NCT05357560: A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
- State
- Completed
- Phase
- Phase 1
- People
- 107 taking part
- Started
- 10 Jul 2023
- Primary completion
- 11 Dec 2025
- Arms
- Group 1 - Infants R21 delayed 3rd dose, Group 2 - Infants R21 standard regimen, Group 3 - Adults RH5.2 low dose, standard regimen, Group 4 - Adults RH5.2 high dose, standard regimen, Group 5 - Adults RH5.2 and R21 low dose, standard regimen, Group 6 - Infants RH5.2 standard regimen, Group 7 - Infants RH5.2, delayed 3rd dose, Group 8 - Infants RH5.2 and R21, standard regimen, Group 9 - Infants RH5.2 and R21, delayed 3rd dose
- Results
- None posted
- 3 May 2022: Trial registered
- 10 Jul 2023: Trial started
- 11 Dec 2025: Trial completed